Does BCBS Alabama cover Zepbound?

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation meeting threshold (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 23 kg/m2 for qualifying Asian ethnicities)
• Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
• Documentation of reduced-calorie diet and increased physical activity as adjunct

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended
• Pregnancy

Policy note: Covers both Zepbound subcutaneous injection solution vial and Zepbound KwikPen formulations. Adult-only FDA indication for weight loss (no pediatric indication for tirzepatide at time of policy). The 5% weight loss threshold at 12 weeks is cited from guidelines as the efficacy assessment standard applicable to all weight management agents.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation meeting threshold (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 23 kg/m2 for qualifying Asian ethnicities)
• Documentation of qualifying weight-related comorbidity if BMI 27–29.9 kg/m2
• Documentation of reduced-calorie diet and increased physical activity as adjunct

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, At least 5% weight loss after 12 weeks at a therapeutic dose is required for continuation per guideline-based efficacy assessment standard cited in document, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended
• Pregnancy

Policy note: Covers both Zepbound subcutaneous injection solution vial and Zepbound KwikPen formulations. Adult-only FDA indication for weight loss (no pediatric indication for tirzepatide at time of policy). The 5% weight loss threshold at 12 weeks is cited from guidelines as the efficacy assessment standard applicable to all weight management agents.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate-to-severe OSA confirmed by polysomnography (PSG) or home sleep apnea test (HSAT) with AHI or REI >= 15 events/hour
• Baseline BMI documentation >= 30 kg/m2
• Sleep study results (PSG or HSAT report) documenting AHI/REI severity
• Documentation of reduced-calorie diet and increased physical activity as adjunct

Not covered when

• Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria cited in document)
• Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Daytime hypercapnia
• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended
• Pregnancy

Policy note: OSA indication requires obesity (BMI >= 30) per FDA label. Moderate-to-severe OSA defined as AHI >= 15 events/hour (moderate 15-29, severe >= 30). The SURMOUNT-OSA program enrolled both PAP-naive (Trial 1) and PAP-using (Trial 2) patients; PAP trial is NOT required as a prerequisite. AHI from PSG is the preferred diagnostic index; REI from HSAT is acceptable but may underestimate severity. RDI may identify arousal-based disease not fully captured by AHI/REI. Document extensively discusses OSA diagnostic methodology (PSG vs HSAT, AHI vs REI vs RDI, hypopnea scoring rules) as clinical rationale. The osa_ahi_min of 15 is inferred from 'moderate-to-severe' OSA definition per AASM standard referenced in the document; the document does not explicitly state a specific AHI threshold as a PA requirement but references moderate-to-severe as the qualifying severity. PAP therapy use is not required prior to Zepbound; patients on PAP or not on PAP may qualify.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate-to-severe OSA confirmed by polysomnography (PSG) or home sleep apnea test (HSAT) with AHI or REI >= 15 events/hour
• Baseline BMI documentation >= 30 kg/m2
• Sleep study results (PSG or HSAT report) documenting AHI/REI severity
• Documentation of reduced-calorie diet and increased physical activity as adjunct

Not covered when

• Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria cited in document)
• Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Daytime hypercapnia
• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended
• Pregnancy

Policy note: OSA indication requires obesity (BMI >= 30) per FDA label. Moderate-to-severe OSA defined as AHI >= 15 events/hour (moderate 15-29, severe >= 30). The SURMOUNT-OSA program enrolled both PAP-naive (Trial 1) and PAP-using (Trial 2) patients; PAP trial is NOT required as a prerequisite. AHI from PSG is the preferred diagnostic index; REI from HSAT is acceptable but may underestimate severity. RDI may identify arousal-based disease not fully captured by AHI/REI. Document extensively discusses OSA diagnostic methodology (PSG vs HSAT, AHI vs REI vs RDI, hypopnea scoring rules) as clinical rationale. The osa_ahi_min of 15 is inferred from 'moderate-to-severe' OSA definition per AASM standard referenced in the document; the document does not explicitly state a specific AHI threshold as a PA requirement but references moderate-to-severe as the qualifying severity. PAP therapy use is not required prior to Zepbound; patients on PAP or not on PAP may qualify.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ALBP_Weight_Management_PAQL_ProgSum.pdf